Clinical Trials for Lung Cancers
30 Open Trials
| Trial Type & Disease | Protocol No. & Open Date | Summary |
|---|---|---|
| Therapeutic Lung; Non Small Cell | VICCTHN1307 06/06/2013 | A Phase 2 Study of Neratinib and Neratinib Plus Temsirolimus in Patients with Non-Small Cell Lung Cancer Carrying Known HER2 Activating Mutations |
| Therapeutic Lung | VICCTHN1297 02/07/2013 | A Single-Arm Phase 2 Study of BMS-936558 in Subjects with Advanced or Metastatic Squamous Cell Non-Small Cell Lung Cancer Who have Received at Least Two Prior Systemic Regimens |
| Therapeutic Lung | VICCTHN1281 01/23/2013 | An Open-Label Randomized Phase III Trial of BMS-936558 versus Docetaxel in Previously Treated Metastatic Non-squamous Non-small cell Lung Cancer (NSCLC) |
| Therapeutic Lung | VICCTHN1262 01/07/2013 | An Open-label Randomized Phase III Trial of BMS-936558 versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer |
| Therapeutic Lung; Small Cell | VICCTHN1189 12/14/2012 | Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab plus Etoposide/Platinum versus Etoposide/Platinum in Subjects with Newly Diagnosed Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) |
| Therapeutic Lung; Non Small Cell | VICCTHN1242 10/24/2012 | A Phase IB, Multi-Center,Open-Label Study of the MTOR Kinase Inhibitor CC-223 in Combination with Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer |
| Therapeutic Lung; Small Cell | VICCTHN1212 09/12/2012 | Randomized Phase II Study of Single Agent OSI-906, an Oral, Small Molecule, Tyrosine Kinase Inhibitor (TKI) of the Insulin Growth Factor-1 Receptor (IGF-1R) Versus Topotecan for the Treatment of Patients with Relapsed Small Cell Lung Cancer (SCLC) |
| Therapeutic Lung | VICCTHN1122 08/21/2012 | Open label two-stage study of orally administered BKM120 in patients with metastatic non-small cell lung cancer with activated PI3K pathway |
| Therapeutic Lung; Non Small Cell | VICCTHN1123 07/27/2012 | A Phase II Study of the Selective BRAF Kinase Inhibitor GSK2118436 in Subjects with Advanced Non-Small Cell Lung Cancer and BRAF. Mutations |
| Therapeutic Adrenocortical; Bladder; Breast; Cervical; Colon; Dermatologic; Esophageal; GIST; Gastric/Gastroesophageal; Gynecologic; Head/Neck; Kidney (Renal Cell); Liver; Lung; Multiple Myeloma; Neuroendocrine; Ovarian; Pancreatic; Prostate; Rectal; Sarcoma; Small Cell; Uterine | VICCMD1188 06/08/2012 | An Open-Label, Phase II Study of Vemurafenib in Patients with BRAF V600 Mutation-Positive Cancers |
| Therapeutic Non Small Cell | VICCTHO1042 10/11/2011 | A Phase 1-2 Trial of MM-121 in Combination with Erlotinib in Three Groups of Patients with Non-Small Cell Lung Cancer |
| Therapeutic Non Small Cell | VICCTHO1079 07/27/2011 | Phase 3, Randomized, Open-Label Study of the Efficacy and Safety of Crizotinib versus Pemetrexed/Cisplatin or Pemetrexed/Carboplatin in Previously Untreated Patients with Non-Squamous Carcinoma of the Lung Harboring a Translocation or Inversion Event Involving the Anaplastic Lymphoma Kinase (ALK) Gene Locus |
| Therapeutic Lung; Non Small Cell | ECOGTHNE5508 06/29/2011 | Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Premetrexed, or Combination of Bevacizumab and Premtrexed following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC |
| Therapeutic Non Small Cell | ECOGTHO5508-M 02/09/2011 | Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC |
| Therapeutic Lung | ECOGTHO4508-M 12/07/2010 | Three-Arm Randomized Phase II Study of Carboplatin and Paclitaxel in Combination with Cetuximab, IMC-A12 or Both for Advanced Non-small Cell Lung Cancer Patients WhoWill Not Receive Bevacizumab-based Therapy |
| Therapeutic Lung | CTSUTHOC30607-M 02/17/2010 | ARandomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib as Maintenance Therapy in Non-Progressing Patients following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer |
| Therapeutic Lung; Non Small Cell | VICCTHO0730 10/15/2007 | A Phase II Trial of Celecoxib plus Chemotherapy [Docetaxel or Pemetrexed] in Patients with Previously Treated, "COX Dependent" Recurrent Non-Small Cell Lung Cancer (SPORE) |
| Therapeutic Lung; Non Small Cell | ECOGTHOE1505 08/30/2007 | A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (>=4 cm)-IIIA Non-Small Cell Lung Cancer (NSCLC). |
| Therapeutic Non Small Cell | ECOGTHOE1505-M 07/27/2007 | A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB (> or = 4 cm)- IIIA Non-Small Cell Lung Cancer (NSCLC) |
| Correlative Lung | VICCTHN1311 04/12/2013 | Inherited Genetic Risk Factors Common to Lung Cancer and COPD: (LC-COPD) |
| Correlative Lung | VICCTHN1291 03/28/2013 | Early Diagnosis of Pulmonary Nodules Using a Plasma Proteomic Classifier |
| Correlative Lung | VICCTHN1292 03/18/2013 | Validation of Molecular Biomarkers for the Early Detection of Lung Cancer in the Setting of Indeterminate Pulmonary Nodules. (Lung Team Project #2) |
| Correlative Lung; Non Small Cell | VICCTHN1164 11/04/2011 | Molecular Profiles for Lung Cancer Pathogenesis and Detection |
| Correlative Lung | VICCTHO0967 07/27/2010 | Lung Cancer Mutation Consortium Protocol |
| Correlative Lung; Non Small Cell | VICCTHO0547 12/19/2005 | Molecular Fingerprints in Lung Cancer: Predicting Tumor Response to Therapy (SPORE) |
| Correlative Lung | VICCTHO0398 12/04/2003 | Molecular Predictors of Lung Cancer Behavior. (SPORE) |
| Correlative Lung | VICCTHO0373 05/03/2001 | Identification and Validation of Molecular Markers in Lung Cancer (SPORE) |
| Correlative Non Small Cell | VICCTHO0136 05/01/2001 | Molecular Fingerprinting of Lung Cancer (SPORE) |
| Screen, Detect, Diagnose Adrenocortical; Bladder; Breast; Cervical; Colon; Dermatologic; Esophageal; GIST; Gastric/Gastroesophageal; Gynecologic; Head/Neck; Kidney (Renal Cell); Liver; Lung; Multiple Myeloma; Neuroendocrine; Ovarian; Pancreatic; Prostate; Rectal; Sarcoma; Small Cell; Uterine | VICCMD1286 12/17/2012 | Screening Protocol to Detect BRAF V600 Mutation Positive Patients for Enrollment into Clinical Research Studies of Vemurafenib |
| Screen, Detect, Diagnose Lung; Miscellaneous | VICCTHO1078 04/12/2011 | Nashville Early Diagnosis Lung Cancer Project |
You do not have JavaScript enabled. This site works better with JavaScript turned on.
